Situation:

A client was developing a new  apheresis device.  Monitoring complement activation after blood  exposure, they found higher levels compared to historical experience.   The client was concerned this would slow development of the device.

BioPhia Role:

BioPhia was engaged to provide SME  review of the in vitro complement activation data and provide insight  into possible reasons for the apparent levels and suggest the next  steps.

Action:

An initial meeting produced a  document that explained the data in the context of extracorporeal blood  contact and outlined a set of follow-up experiments to resolve any  issues.

Result:

A white paper was generated that  included background on complement activation, the original data and  results from follow-up work.  This was included as an addendum to an  internal report on the device development project.